Heron (Shanghai) Pharmaceutical Science & Technology Co., Ltd.

Heron (Shanghai), a subsidiary of Nanjing Heron Pharmaceutical Science and Technology Co., Ltd., is dedicated to production, sales, technical and regulatory affairs service of APIs, excipients and FDFS globally.

Heron (Shanghai)'s primary business activities include:

1. China Import, registration, market and sales of pharmaceutical excipients
2. China Import, registration and sales of APIs, intermediates and FDFs
3. Globally registration, market and sales of own APIs and FDFs
4. Offer other products of market unmet needs, such as COVID-19 protective products

Founded in 2013, Heron Pharma is a pharmaceutical company adhering to an innovation-driven and product differentiation strategy. It possesses world-leading research and development technology for active vitamin D derivatives, NCEs and first generics. The bulk production of active vitamin D derivative drugs can be provided with diverse DMFs over the world, including Alfacalcidol, Calcipotriol, Paricalcitol, Tacalcitol etc.

Over the past decade, 8 FDFs have been successfully commercialized in China, including the first generics of Tacalcitol Ointment and Regadenoson Injection. And 2 products, Calcitriol Soft Capsules and Ketorolac Tromethamine Injection have been involved in the centralized purchasing of the National Healthcare Security Bureau.